AmoyDx(SZ:300685) Sou Hu Cai Jing·2025-04-01 09:56Company Overview - Xiamen Ade Biological Technology Co., Ltd. specializes in the research, production, and sales of molecular diagnostic products for precision oncology, providing related testing services [2] - The company's main products include targeted drug molecular diagnostic reagents and chemotherapy drug molecular diagnostic reagents, which are used to assess the genetic status of cancer patients [2] - The company holds multiple qualifications, including "National High-tech Enterprise" and "National Enterprise Technology Center," and has received various awards for its research and development efforts [2] Financial Performance - For the third quarter of 2024, the company reported revenue of 848 million yuan, representing a year-on-year increase of 19.84% [3] - The net profit for the same period was 227 million yuan, showing a year-on-year growth of 30.82% [3] - The sales gross margin stood at 84.74% [3] Market Position - As of April 1, the company's stock closed at 23.15 yuan, with a price-to-earnings (PE) ratio of 28.88 times, while the average PE ratio in the medical device industry is 46.46 times [1][3] - The company's total market capitalization is approximately 9.099 billion yuan [1] - In terms of market performance, the company ranked 65th in the industry based on PE ratio [1]